<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33869639</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2314-7156</ISSN><JournalIssue CitedMedium="Internet"><Volume>2021</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Journal of immunology research</Title><ISOAbbreviation>J Immunol Res</ISOAbbreviation></Journal><ArticleTitle>Antiviral Efficacy of the Anesthetic Propofol against Dengue Virus Infection and Cellular Inflammation.</ArticleTitle><Pagination><StartPage>6680913</StartPage><MedlinePgn>6680913</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">6680913</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1155/2021/6680913</ELocationID><Abstract><AbstractText>Propofol, 2,6-diisopropylphenol, is a short-acting intravenous sedative agent used in adults and children. Current studies show its various antimicrobial as well as anti-inflammatory effects. Dengue virus (DENV) is an emerging infectious pathogen transmitted by mosquitoes that causes mild dengue fever and progressive severe dengue diseases. In the absence of safe vaccines and antiviral agents, adjuvant treatments and supportive care are generally administered. This study investigated the antiviral effects of propofol against DENV infection and cellular inflammation by using an <i>in vitro</i> cell model. Treatment with propofol significantly inhibited DENV release 24&#x2009;h postinfection in BHK-21 cells. Furthermore, it also blocked viral protein expression independent of the translational blockade. Propofol neither caused inhibitory effects on endosomal acidification nor prevented dsRNA replication. Either the proinflammatory TNF-<i>&#x3b1;</i> or the antiviral STAT1 signaling was reduced by propofol treatment. These results provide evidence to show the potential antiviral effects of the sedative propofol against DENV infection and cellular inflammation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Ting-Jing Shen et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Ting-Jing</ForeName><Initials>TJ</Initials><Identifier Source="ORCID">0000-0002-1714-0048</Identifier><AffiliationInfo><Affiliation>Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chia-Ling</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jhan</LastName><ForeName>Ming-Kai</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tseng</LastName><ForeName>Po-Chun</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Core Laboratory of Immune Monitoring, Office of Research &amp; Development, Taipei Medical University, Taipei 110, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Satria</LastName><ForeName>Rahmat Dani</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Pathology and Laboratory Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta 55281, Indonesia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Laboratory Installation, Dr. Sardjito Central General Hospital, Yogyakarta 55281, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsing</LastName><ForeName>Chung-Hsi</ForeName><Initials>CH</Initials><Identifier Source="ORCID">0000-0002-6091-5371</Identifier><AffiliationInfo><Affiliation>Department of Medical Research, Chi-Mei Medical Center, Tainan 710, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, Chi-Mei Medical Center, Tainan 710, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Chiou-Feng</ForeName><Initials>CF</Initials><Identifier Source="ORCID">0000-0003-4396-6086</Identifier><AffiliationInfo><Affiliation>Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Core Laboratory of Immune Monitoring, Office of Research &amp; Development, Taipei Medical University, Taipei 110, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Infectious Diseases and Signaling Research, National Cheng Kung University, Tainan 701, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Egypt</Country><MedlineTA>J Immunol Res</MedlineTA><NlmUniqueID>101627166</NlmUniqueID><ISSNLinking>2314-7156</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000777">Anesthetics</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical><Chemical><RegistryNumber>YI7VU623SF</RegistryNumber><NameOfSubstance UI="D015742">Propofol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000777" MajorTopicYN="N">Anesthetics</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003715" MajorTopicYN="N">Dengue</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015742" MajorTopicYN="N">Propofol</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33869639</ArticleId><ArticleId IdType="pmc">PMC8032536</ArticleId><ArticleId IdType="doi">10.1155/2021/6680913</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Angelini G., Ketzler J. T., Coursin D. B. Use of propofol and other nonbenzodiazepine sedatives in the intensive care unit. Critical Care Clinics. 2001;17(4):863&#x2013;880. doi: 10.1016/s0749-0704(05)70184-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0749-0704(05)70184-6</ArticleId><ArticleId IdType="pubmed">11762265</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson S. L., Duke-Novakovski T., Singh B. The immune response to anesthesia: part 2 sedatives, opioids, and injectable anesthetic agents. Veterinary Anaesthesia and Analgesia. 2014;41(6):553&#x2013;566. doi: 10.1111/vaa.12191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vaa.12191</ArticleId><ArticleId IdType="pubmed">24962601</ArticleId></ArticleIdList></Reference><Reference><Citation>Helmy S. A. K., al-Attiyah R. J. The immunomodulatory effects of prolonged intravenous infusion of propofol versus midazolam in critically ill surgical patients. Anaesthesia. 2001;56(1):4&#x2013;8. doi: 10.1046/j.1365-2044.2001.01713.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2044.2001.01713.x</ArticleId><ArticleId IdType="pubmed">11167428</ArticleId></ArticleIdList></Reference><Reference><Citation>Apan T. Z., Apan A., Sahin S., Cakirca M. Antibacterial activity of remifentanil and mixtures of remifentanil and propofol. Journal of Clinical Anesthesia. 2007;19(5):346&#x2013;350. doi: 10.1016/j.jclinane.2007.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinane.2007.02.005</ArticleId><ArticleId IdType="pubmed">17869984</ArticleId></ArticleIdList></Reference><Reference><Citation>Begec Z., Yucel A., Yakupogullari Y., et al. The antimicrobial effects of ketamine combined with propofol: an in vitro study. Brazilian Journal of Anesthesiology. 2013;63(6):461&#x2013;465. doi: 10.1016/j.bjane.2012.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bjane.2012.09.004</ArticleId><ArticleId IdType="pubmed">24565343</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T., Mallewa M. Dengue and other emerging flaviviruses. The Journal of Infection. 2001;42(2):104&#x2013;115. doi: 10.1053/jinf.2001.0802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/jinf.2001.0802</ArticleId><ArticleId IdType="pubmed">11531316</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanaway J. D., Shepard D. S., Undurraga E. A., et al. The global burden of dengue: an analysis from the Global Burden of Disease Study 2013. The Lancet Infectious Diseases. 2016;16(6):712&#x2013;723. doi: 10.1016/S1473-3099(16)00026-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(16)00026-8</ArticleId><ArticleId IdType="pmc">PMC5012511</ArticleId><ArticleId IdType="pubmed">26874619</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory C. J., Tomashek K. M. Management of severe dengue. Pediatric Critical Care Medicine. 2012;13(1):125&#x2013;125; author reply 126. doi: 10.1097/PCC.0b013e318219181b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0b013e318219181b</ArticleId><ArticleId IdType="pubmed">22222665</ArticleId></ArticleIdList></Reference><Reference><Citation>Lum L. C., Lam S. K., George R., Devi S. Fulminant hepatitis in dengue infection. The Southeast Asian Journal of Tropical Medicine and Public Health. 1993;24(3):467&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pubmed">8160054</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen T. J., Chen C. L., Jhan M. K., Tseng P. C., Lin C. F. CNS immune profiling in a dengue virus-infected immunocompetent outbred ICR mice strain. Frontiers in Cellular and Infection Microbiology. 2020;10, article 557610 doi: 10.3389/fcimb.2020.557610.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2020.557610</ArticleId><ArticleId IdType="pmc">PMC7539834</ArticleId><ArticleId IdType="pubmed">33072626</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta E. G., Bartenschlager R. The quest for host targets to combat dengue virus infections. Current Opinion in Virology. 2016;20:47&#x2013;54. doi: 10.1016/j.coviro.2016.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2016.09.003</ArticleId><ArticleId IdType="pubmed">27648486</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao J. C., HuangFu W. C., Tsai T. T., et al. The antiparasitic drug niclosamide inhibits dengue virus infection by interfering with endosomal acidification independent of mTOR. PLoS Neglected Tropical Diseases. 2018;12(8, article e0006715) doi: 10.1371/journal.pntd.0006715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0006715</ArticleId><ArticleId IdType="pmc">PMC6117097</ArticleId><ArticleId IdType="pubmed">30125275</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H. C., Hofman F. M., Kung J. T., Lin Y. D., Wu-Hsieh B. A. Both virus and tumor necrosis factor alpha are critical for endothelium damage in a mouse model of dengue virus-induced hemorrhage. Journal of Virology. 2007;81(11):5518&#x2013;5526. doi: 10.1128/JVI.02575-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02575-06</ArticleId><ArticleId IdType="pmc">PMC1900309</ArticleId><ArticleId IdType="pubmed">17360740</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y. L., Lin Y. S., Chen C. L., et al. Activation of Nrf2 by the dengue virus causes an increase in CLEC5A, which enhances TNF-&#x3b1; production by mononuclear phagocytes. Scientific Reports. 2016;6(1, article 32000) doi: 10.1038/srep32000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep32000</ArticleId><ArticleId IdType="pmc">PMC4999957</ArticleId><ArticleId IdType="pubmed">27561946</ArticleId></ArticleIdList></Reference><Reference><Citation>Jhan M. K., HuangFu W. C., Chen Y. F., et al. Anti-TNF-&#x3b1; restricts dengue virus-induced neuropathy. Journal of Leukocyte Biology. 2018;104(5):961&#x2013;968. doi: 10.1002/JLB.MA1217-484R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.MA1217-484R</ArticleId><ArticleId IdType="pubmed">30044892</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng X., Li C., Yu W., et al. Propofol attenuates hypoxia-induced inflammation in BV2 microglia by inhibiting oxidative stress and NF-&#x3ba;B/Hif-1&#x3b1; signaling. BioMed Research International. 2020;2020:11. doi: 10.1155/2020/8978704.8978704</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/8978704</ArticleId><ArticleId IdType="pmc">PMC7204316</ArticleId><ArticleId IdType="pubmed">32420378</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu G. J., Lin Y. W., Tsai H. C., Lee Y. W., Chen J. T., Chen R. M. Sepsis-induced liver dysfunction was ameliorated by propofol _via_ suppressing hepatic lipid peroxidation, inflammation, and drug interactions. Life Sciences. 2018;213:279&#x2013;286. doi: 10.1016/j.lfs.2018.10.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2018.10.038</ArticleId><ArticleId IdType="pubmed">30352244</ArticleId></ArticleIdList></Reference><Reference><Citation>Nseir S., Makris D., Mathieu D., Durocher A., Marquette C. H. Intensive care unit-acquired infection as a side effect of sedation. Critical Care. 2010;14(2, article R30) doi: 10.1186/cc8907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc8907</ArticleId><ArticleId IdType="pmc">PMC2887136</ArticleId><ArticleId IdType="pubmed">20226064</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinmann E., Ciesek S., Friesland M., Erichsen T. J., Pietschmann T. Prolonged survival of hepatitis c virus in the anesthetic propofol. Clinical Infectious Diseases. 2011;53(9):963&#x2013;964. doi: 10.1093/cid/cir530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cir530</ArticleId><ArticleId IdType="pubmed">21880582</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan V. C. Dengue: moving from current standard of care to state-of-the-art treatment. Current Treatment Options in Infectious Diseases. 2014;6(3):208&#x2013;226. doi: 10.1007/s40506-014-0025-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40506-014-0025-1</ArticleId><ArticleId IdType="pmc">PMC4431705</ArticleId><ArticleId IdType="pubmed">25999799</ArticleId></ArticleIdList></Reference><Reference><Citation>Tricou V., Minh N. N., Van T. P., et al. A randomized controlled trial of chloroquine for the treatment of dengue in vietnamese adults. PLoS Neglected Tropical Diseases. 2010;4(8, article e785) doi: 10.1371/journal.pntd.0000785.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0000785</ArticleId><ArticleId IdType="pmc">PMC2919376</ArticleId><ArticleId IdType="pubmed">20706626</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehorn J., Nguyen C. V. V., Khanh L. P., et al. Lovastatin for the treatment of adult patients with dengue: a randomized, double-blind, placebo-controlled trial. Clinical Infectious Diseases. 2015;62(4):468&#x2013;476. doi: 10.1093/cid/civ949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/civ949</ArticleId><ArticleId IdType="pmc">PMC4725386</ArticleId><ArticleId IdType="pubmed">26565005</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz-Oliveira C., Freire J. M., Conceicao T. M., Higa L. M., Castanho M. A. R. B., Da Poian A. T. Receptors and routes of dengue virus entry into the host cells. FEMS Microbiology Reviews. 2015;39(2):155&#x2013;170. doi: 10.1093/femsre/fuu004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/femsre/fuu004</ArticleId><ArticleId IdType="pubmed">25725010</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C. K., Tseng C. K., Wu Y. H., et al. Cyclooxygenase&#x2010;2 facilitates dengue virus replication and serves as a potential target for developing antiviral agents. Scientific Reports. 2017;7(1, article 44701) doi: 10.1038/srep44701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep44701</ArticleId><ArticleId IdType="pmc">PMC5357798</ArticleId><ArticleId IdType="pubmed">28317866</ArticleId></ArticleIdList></Reference><Reference><Citation>Inada T., Kubo K., Kambara T., Shingu K. Propofol inhibits cyclo-oxygenase activity in human monocytic THP-1 cells. Canadian Journal of Anaesthesia. 2009;56(3):222&#x2013;229. doi: 10.1007/s12630-008-9035-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12630-008-9035-0</ArticleId><ArticleId IdType="pubmed">19247743</ArticleId></ArticleIdList></Reference><Reference><Citation>Inada T., Kubo K., Ueshima H., Shingu K. Intravenous anesthetic propofol suppresses prostaglandin E2 production in murine dendritic cells. Journal of Immunotoxicology. 2011;8(4):359&#x2013;366. doi: 10.3109/1547691X.2011.620036.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/1547691X.2011.620036</ArticleId><ArticleId IdType="pubmed">22035152</ArticleId></ArticleIdList></Reference><Reference><Citation>Steer S. A., Corbett J. A. The role and regulation of COX-2 during viral infection. Viral Immunology. 2003;16(4):447&#x2013;460. doi: 10.1089/088282403771926283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/088282403771926283</ArticleId><ArticleId IdType="pubmed">14733733</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexanian A., Sorokin A. Cyclooxygenase 2: protein-protein interactions and posttranslational modifications. Physiological Genomics. 2017;49(11):667&#x2013;681. doi: 10.1152/physiolgenomics.00086.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physiolgenomics.00086.2017</ArticleId><ArticleId IdType="pmc">PMC5792139</ArticleId><ArticleId IdType="pubmed">28939645</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawan B., Kao Y. H., Goto S., et al. Propofol pretreatment attenuates LPS-induced granulocyte-macrophage colony- stimulating factor production in cultured hepatocytes by suppressing MAPK/ERK activity and NF-&#x3ba;B translocation. Toxicology and Applied Pharmacology. 2008;229(3):362&#x2013;373. doi: 10.1016/j.taap.2008.01.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.taap.2008.01.044</ArticleId><ArticleId IdType="pubmed">18387647</ArticleId></ArticleIdList></Reference><Reference><Citation>Visvabharathy L., Xayarath B., Weinberg G., Shilling R. A., Freitag N. E. Propofol increases host susceptibility to microbial infection by reducing subpopulations of mature immune effector cells at sites of infection. PLoS One. 2015;10(9, article e0138043) doi: 10.1371/journal.pone.0138043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0138043</ArticleId><ArticleId IdType="pmc">PMC4575148</ArticleId><ArticleId IdType="pubmed">26381144</ArticleId></ArticleIdList></Reference><Reference><Citation>Kittigul L., Temprom W., Sujirarat D., Kittigul C. Determination of tumor necrosis factor-alpha levels in dengue virus infected patients by sensitive biotin-streptavidin enzyme-linked immunosorbent assay. Journal of Virological Methods. 2000;90(1):51&#x2013;57. doi: 10.1016/s0166-0934(00)00215-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0166-0934(00)00215-9</ArticleId><ArticleId IdType="pubmed">11011080</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>